secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001664710-24-000016
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics reports Q4 2023 net loss of $40.2M, cash $331.1M; extends runway into 2027
--------------------------------------------------------------------------------

- Net loss of $40.2M in Q4 2023 ($153.0M for FY) vs $29.7M and $104.7M in prior year periods.
- Revenue of $0.2M in 2023 from license agreement with Hansoh; no revenue in 2022.
- R&D expenses rose to $37.5M in Q4 (FY $135.3M) driven by Phase 2 trials of KER-050 and KER-012.
- Cash and equivalents $331.1M at Dec 31, 2023; January 2024 public offering of 4.025M shares at $40/sh adds net proceeds, funding into 2027.
- Anticipated milestones: Phase 3 trial design for KER-050 in MDS in H1 2024; data readouts throughout 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000016/0001664710-24-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000016/kros-20240228.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer